CYP2D6 testing for breast cancer patients: is there more to the story?
Henry, N.L.; Hayes, D.F.; Rae, J.M.
Oncology 23(14): 1236; 1243, 1249
2009
ISSN/ISBN: 0890-9091 PMID: 20120836 Document Number: 630112
Document emailed within 1 workday
Related Documents
Lipkus, I.M.; Iden, D.; Terrenoire, J.; Feaganes, J.R. 1999: Relationships among breast cancer concern, risk perceptions, and interest in genetic testing for breast cancer susceptibility among African-American women with and without a family history of breast cancer Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 8(6): 533-539Copur, M.S. 2019: Universal Genetic Testing for all Breast Cancer Patients Oncology 33(8)
Friedenson, B.; Friedenson, H. 2002: Genetic testing for breast and ovarian cancer for women with a family history of breast cancer: weighing conflicting evidence about oral contraceptives Medgenmed: Medscape General Medicine 4(3): 3
Chamberlin, M.D.; Kaufman, P.A. 2014: HER2-positive breast cancer: the story goes on Oncology 28(4): 290; 292-293
Elwood, J.M. 1999: Public health aspects of breast cancer gene testing in Canada. Part 2: selection for and effects of testing Chronic Diseases in Canada 20(1): 14-20
Merritt, D.D.; Liles, B.Z. 1987: Story grammar ability in children with and without language disorder: story generation, story retelling, and story comprehension Journal of Speech and Hearing Research 30(4): 539-552
Merritt, D.D.; Liles, B.Z. 1987: Story grammar ability in children with and without language disorder: story generation, story retelling, and story comprehension Journal of Speech and Hearing Research 30(4): 539-552
Haid, M.; Lembersky, B. 1998: Has genetic testing for breast cancer come of age? Seminars in Oncology 25(1): Xxix-Xxxi Xxxv-Xxxv; Discussion Xx
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82
Ansquer, Y.; Gautier, C.; Fourquet, A.; Asselain, B.; Stoppa-Lyonnet, D. 1998: Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group Lancet 352(9127): 541
Cummings, S.; Olopade, O. 1998: Predisposition testing for inherited breast cancer Oncology 12(8): 1227-1241; Discussion: 1241-1242
Hooning, M.J.; van Dongen, J.A.; Went, G. 1991: Changing indications for breast conserving therapy: proportion of patients with operable breast cancer suitable for breast conservation Netherlands Journal of Surgery 43(4): 102-104
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. I. Prognostic factors in patients with node-negative (N0) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 159-163
Rudan, I.; Skorić, T.; Rudan, N. 1994: Breast cancer prognosis. II. Prognostic factors in patients with node-positive (N1-3) breast cancer Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 48(4-5): 165-170
Abdalla, I.; Thisted, R.A.; Heimann, R. 2000: The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy Cancer Journal 6(4): 266-272
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Li, Y.-h.; Tie, J.; Wu, H.; Li, X.-f.; Xu, B.; Cai, Y. 2013: Clinical observation of accelerated partial-breast intensity-modulated radiotherapy in patients with early-stage breast cancer after breast-conserving surgery Zhonghua Yi Xue Za Zhi 93(12): 924-926
Schultz, D.C.; Bazel, S.; Wright, L.M.; Tucker, S.; Lange, M.K.; Tachovsky, T.; Longo, S.; Niedbala, S.; Alhadeff, J.A. 1994: Western blotting and enzymatic activity analysis of cathepsin D in breast tissue and sera of patients with breast cancer and benign breast disease and of normal controls Cancer Research 54(1): 48-54
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508